Clinical Personalized Medicine for Parkinson's Disease and Implications on Sleep Dysfunction

Personalized medicine (PM) for Parkinson's disease (PD) can range from precision genomic therapies such as ambroxol in glucocerebrosidase mutation-linked PD to treatment tailored for sleep dysfunction in nonmotor subtypes of PD. Additionally, in future pharmacogenetics may also play a part by i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sleep medicine clinics Ročník 20; číslo 3; s. 417
Hlavní autoři: Metta, Vinod, Popławska-Domaszewicz, Karolina, Chen, Rosabel, Chaudhuri, K Ray
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.09.2025
Témata:
Humans
Parkinson Disease - complications
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - therapy
Precision Medicine - methods
Sleep Wake Disorders - drug therapy
Sleep Wake Disorders - etiology
Sleep Wake Disorders - therapy
Pharmacogenetics
Sleep dysfunction
Precision medicine
Genomic medicine
Insomnia pharmacogenetics
Personalised medicine
Subtype
Parkinson’s disease
ISSN:1556-4088
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Personalized medicine (PM) for Parkinson's disease (PD) can range from precision genomic therapies such as ambroxol in glucocerebrosidase mutation-linked PD to treatment tailored for sleep dysfunction in nonmotor subtypes of PD. Additionally, in future pharmacogenetics may also play a part by identification of PD patients susceptible to specific sleep problems such as sudden onset of sleep and facilitate avoiding drugs that may cause these side effects. Age, physical exercise, comorbidities can also drive quality of sleep in PD and form important part of the Parkinson's dashboard-led strand of PM.
ISSN:1556-4088
DOI:10.1016/j.jsmc.2025.06.006